Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 0%
Buy 13%
Hold 88%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst is currently facing challenges with stabilizing and growing their go-forward business after the divestiture of Vitalware, which accounted for a larger portion of their recent adj-EBITDA than expected. Further divestitures may be in the works but it is uncertain if they will have a significant impact on the company's financials. Their recent revenue decline can be attributed to the restructuring of lower-margin services, but their technology segment continues to show promise and beat consensus.

Bears say

Health Catalyst is facing a challenging operating environment with a longer sales cycle and increased competition in the healthcare data and analytics market. Their recent guidance revisions and decline in annual revenue for FY27 are mainly driven by the migration of legacy contracts to newer, lower-priced offerings, leading to increased pressure on customer retention and a negative mix shift in their business. Additionally, the overall slowdown in M&A activity and focus on profitability could further impact their growth potential. Overall, the negative outlook on Health Catalyst is driven by these fundamental factors and the potential for continued underperformance in the near term.

HCAT has been analyzed by 8 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 13% recommend Buy, 88% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 8 analysts, HCAT has a Hold consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.